Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

TWBXX Mar. 22 at 6:06 PM

$BCTX Per AI co-pilot: In oncology, especially late‑line metastatic breast cancer, survival beyond 2–3 years is considered a long‑term tail. BriaCell now has multiple patients in that range.

0 · Reply

TWBXX Mar. 22 at 6:02 PM

$BCTX Once they release some of the updated long-term survival data from Phase 2, and with fully diluted shares of only 14 million, this stock will rocket upward quickly from the current share price of $4.47!

0 · Reply

TWBXX Mar. 22 at 5:57 PM

$BCTX Per AI co-pilot: BriaCell reported that 9 of 25 patients treated since 2022 remain alive beyond 18–47 months, which is far above expected survival for heavily pretreated metastatic breast cancer. This is the strongest long‑tail signal they’ve ever released. 2. Earlier updates already showed a survival tail forming 52% of the most recent 25‑patient cohort surpassed one year of survival. Several patients reached 30–38 months even in 2025 updates. These earlier signals are now reinforced by the 2026 update

0 · Reply

TWBXX Mar. 22 at 5:51 PM

$BCTX AI co-pilot: Yes — based on the newest verified disclosures, long‑term survival in BriaCell’s Phase 2 metastatic breast cancer trial is no longer speculative. It is now demonstrated in a meaningful subset of patients, with survival durations far beyond what is typical for this late‑line population.

0 · Reply

Goodstockday Mar. 22 at 12:12 AM

$BCTX I just don’t know if there has been enough post-treatment time for there to be great results in the phase 3. Maybe, there will be very short survival in the control group given the level of pretreatment. Turning attention to the phase 2. Could there be long term survival there that is attention worthy? Welcome thoughts on either. Right now, I think there is much greater potential for big results near year end.

0 · Reply

JediGreen Mar. 21 at 11:42 PM

$BCTX Still got a sneaking suspicion of a big naked short seller in this stock with shares not accounted for or showing up in the average total of short shares. Bullish Baby

0 · Reply

Dadisong Mar. 21 at 7:12 PM

$BCTX es una empresa dirigida por un Judío, a está gente no le interesa el dinero ya es súper Rico, sólo le interesa y satisface joder al pobre y arruinarle más. No esperéis nada de ésta empresa nunca subirá y con el tiempo desaparecerá.

0 · Reply

GoldenChic Mar. 20 at 2:59 PM

BINI $HUBC scam of the century $BCTX

0 · Reply

JediGreen Mar. 19 at 5:54 AM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html

0 · Reply

SmallCapGrowth Mar. 18 at 6:00 PM

$BCTX to showcase momentum at AACR - ALERTS, HOT STOCKS & CHARTS https://investorshangout.com/post/view?id=6820505

0 · Reply

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

Wed, 18 Mar 2026 07:30:00 -0400 - 5 days ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 13 days ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 18 days ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 4 weeks ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

Wed, 18 Feb 2026 17:30:00 -0500 - 4 weeks ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Tue, 17 Feb 2026 07:30:00 -0500 - 4 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 7 weeks ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

Wed, 28 Jan 2026 07:30:00 -0500 - 7 weeks ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 7 weeks ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

Tue, 27 Jan 2026 07:30:00 -0500 - 7 weeks ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 2 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 2 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 2 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 2 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 2 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 2 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 2 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 2 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 2 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:08:02.000Z - 2 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 2 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

Tue, 13 Jan 2026 07:30:00 -0500 - 2 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Thu, 18 Dec 2025 07:30:00 -0500 - 3 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T13:29:00.000Z - 3 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

Wed, 10 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T13:34:16.000Z - 3 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

Tue, 09 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:50:27.000Z - 3 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

Tue, 02 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

2025-12-01T12:53:14.000Z - 4 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

Tue, 25 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T13:28:07.000Z - 4 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

Thu, 20 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Tue, 18 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Tue, 04 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

2025-10-28T08:01:00.000Z - 5 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-27T19:05:00.000Z - 5 months ago

Top 3 Earnings Acceleration Buys for November

2025-10-22T12:51:17.000Z - 5 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

Wed, 22 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2025-10-21T20:52:14.000Z - 5 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T13:25:38.000Z - 5 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T12:50:54.000Z - 5 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

Tue, 21 Oct 2025 07:50:00 -0400 - 5 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Tue, 21 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

2025-10-20T13:31:42.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Biomarker Data in Phase 3 Breast Cancer Study

Mon, 20 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

2025-10-13T13:27:39.000Z - 5 months ago

BriaCell (BCTX) to Present Key Phase 3 Study Data at ESMO Congress 2025

Oct 13, 2025, 7:30 AM EDT - 5 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 6 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 7 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 7 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 7 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 7 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 8 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 8 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 8 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 9 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 9 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 9 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 9 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 10 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 10 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 10 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 11 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 11 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

TWBXX Mar. 22 at 6:06 PM

$BCTX Per AI co-pilot: In oncology, especially late‑line metastatic breast cancer, survival beyond 2–3 years is considered a long‑term tail. BriaCell now has multiple patients in that range.

0 · Reply

TWBXX Mar. 22 at 6:02 PM

0 · Reply

TWBXX Mar. 22 at 5:57 PM

0 · Reply

TWBXX Mar. 22 at 5:51 PM

0 · Reply

Goodstockday Mar. 22 at 12:12 AM

0 · Reply

JediGreen Mar. 21 at 11:42 PM

$BCTX Still got a sneaking suspicion of a big naked short seller in this stock with shares not accounted for or showing up in the average total of short shares. Bullish Baby

0 · Reply

Dadisong Mar. 21 at 7:12 PM

0 · Reply

GoldenChic Mar. 20 at 2:59 PM

BINI $HUBC scam of the century $BCTX

0 · Reply

JediGreen Mar. 19 at 5:54 AM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html

0 · Reply

SmallCapGrowth Mar. 18 at 6:00 PM

$BCTX to showcase momentum at AACR - ALERTS, HOT STOCKS & CHARTS https://investorshangout.com/post/view?id=6820505

0 · Reply

SmallCapGrowth Mar. 18 at 5:34 PM

$BCTX BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference https://www.globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert @smallcapvoice

0 · Reply

SmallCapGrowth Mar. 18 at 4:25 PM

Daily Hot Plays : $BCTX raises awareness on their positive... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177409709 via @Investors_Hub

0 · Reply

SmallCapGrowth Mar. 18 at 3:53 PM

🚨 $BCTX AACR BREAKTHROUGH ALERT 🚨💯🚀 TODAY (March 18): BriaCell announces they will present POSITIVE Clinical Data from pivotal Phase 3 Bria-IMT™ + strong Preclinical Data for next-gen Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Annual Meeting! https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html ✅ Heavily pretreated metastatic breast cancer patients maintained quality of life + favorable safety profile (Phase 3 + Phase 2 data) ✅ Bria-OTS+ shows powerful activation of T-cells, NK cells & more across breast, prostate, lung & melanoma — broad cancer killer potential ✅ Four posters dropping April 17-22 in San Diego 🔥 DYOR | #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert @smallcapvoice

0 · Reply

tbagoni Mar. 18 at 3:47 PM

$BCTX Anyone know why down today? Although it is kind of low volume!

0 · Reply

SmallCapGrowth Mar. 18 at 3:45 PM

Daily Hot Plays : $BCTX raises awareness on their positive... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177409709 via @Investors_Hub

0 · Reply

SmallCapGrowth Mar. 18 at 3:39 PM

$BCTX raises awareness on their positive Phase 3 data for Bria-IMT™ and new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer. Read more about the posters here: https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html

0 · Reply

SmallCapGrowth Mar. 18 at 3:34 PM

$BCTX to showcase momentum at AACR 2026 BriaCell will present positive Phase 3 data for Bria-IMT™ plus new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer. Read more about the posters here: https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert

0 · Reply

Kirubin Mar. 18 at 1:56 PM

$BCTX you cannot write this shit up! Always finds a way to make BAG holders!😅

0 · Reply

kellymone2 Mar. 18 at 12:50 PM

$BCTX back to 6$ soon

1 · Reply

jfun1 Mar. 18 at 11:54 AM

$BCTX Abstract Abstract is embargoed at this time.

0 · Reply

SmallCapVoice Mar. 18 at 11:39 AM

$BCTX to showcase momentum at AACR 2026 BriaCell will present positive Phase 3 data for Bria-IMT™ plus new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer. Read more about the posters here: https://www.globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html

0 · Reply

2maligators Mar. 18 at 1:38 AM

$BCTX can someone give us a rundown on the posters…

1 · Reply

Market Cap	30.31M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	173,900
Avg Vol	575,164
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	50%
Beta	1.46
Analysts	Strong Buy
Price Target	$40.00